Related Experiment Video

Updated: Mar 11, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Evolving therapies for hepatitis C virus in chronic kidney disease: the beginning of a new era

Craig E Gordon1, Claudia Nader

  • 1aRenal Section, Department of Medicine, Boston University School of Medicine bDivision of Infectious Diseases, Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.

Current Opinion in Nephrology and Hypertension
|December 2, 2016
PubMed
Abstract

Insights

New direct-acting antiviral (DAA) agents effectively treat chronic hepatitis C virus infection, achieving high cure rates in patients with chronic kidney disease (CKD) and those undergoing hemodialysis or kidney transplantation.

Area of Science:

  • Hepatology
  • Nephrology
  • Virology

Background:

  • Chronic hepatitis C virus (HCV) infection poses significant health challenges, particularly for patients with impaired kidney function.
  • Traditional treatments for HCV have limitations, especially in populations with chronic kidney disease (CKD).

Purpose of the Study:

  • To review recent advancements in treating chronic hepatitis C virus infection.
  • To focus on the efficacy of direct-acting antivirals (DAAs) in patients with advanced CKD, on hemodialysis, and kidney transplant recipients.

Main Methods:

  • Review of current literature on direct-acting antiviral (DAA) therapies for hepatitis C virus.
  • Analysis of evidence pertaining to DAA use in specific patient populations with kidney disease.

Main Results:

  • Direct-acting antiviral (DAA) agents target specific viral proteins, effectively inhibiting hepatitis C virus replication.
  • Sustained virologic response rates exceeding 90% are observed with DAAs in the general population.
  • Emerging data indicate comparable high sustained virologic response rates for DAA regimens in patients with CKD stages 4-5, hemodialysis patients, and kidney transplant recipients.

Conclusions:

  • Direct-acting antiviral (DAA) agents demonstrate high efficacy in treating chronic hepatitis C virus infection across CKD populations.
  • Strategic timing of DAA treatment is crucial for optimizing access to kidney transplantation for eligible patients.

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Related Concept Videos

Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
518
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
864
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
931
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
565
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246